Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea
NCT00039026 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 377
Last updated 2015-02-24
Summary
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (sulfonylurea) throughout the study.
Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
Interventions
- DRUG
-
AC2993
Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
- DRUG
-
AC2993
Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
- DRUG
-
Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
- DRUG
-
Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 16 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-02-28
- Primary Completion
- 2003-08-31
- Completion
- 2003-08-31
Countries
- United States
Study Locations
More Related Trials
-
A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes
NCT00924534 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients
NCT00690287 ·Status: COMPLETED ·Phase: PHASE1
-
A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
NCT03985293 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
NCT01392677 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.
NCT02288273 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes
NCT01396187 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients
NCT01242215 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
NCT05158244 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
NCT00856908 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
NCT03770728 ·Status: TERMINATED ·Phase: PHASE3
-
To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin
NCT00768105 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)
NCT01240980 ·Status: COMPLETED ·Phase: PHASE1
-
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
NCT01285518 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus
NCT04552470 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)
NCT02935712 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus
NCT02897219 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)
NCT00972322 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.
NCT00286468 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
NCT06579105 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus
NCT01023945 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus
NCT00882726 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects
NCT00162305 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers
NCT00933062 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
NCT01294423 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
NCT02926937 ·Status: COMPLETED ·Phase: PHASE3